VRCA · Verrica Pharmaceuticals Inc.
$5.17
-0.28 (-5.06%)
At close · Jul 24
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed May 12, 2026
Market Cap
$86.24M
Shares
17.18M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$35.58M
+370.2%
FY2025
Net Income
-$17.89M
+76.6%
FY2025
Gross Margin
65.64%
-24.6pp
FY2024
Operating Margin
-34.25%
+837pp
FY2025
Diluted EPS
-$1.68
+88.6%
FY2025
Operating Cash Flow
-$17.63M
+71.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $37.16M | $35.58M | $7.57M | $5.12M | $9.03M | $12M | — | — | — | |
| $2.6M | — | $2.6M | $500K | — | — | — | — | — | |
| $4.58M | — | $4.97M | $4.62M | — | — | — | — | — | |
| — | — | 65.64% | 90.24% | — | — | — | — | — | |
| $3.86M | $8.86M | $11.84M | $20.3M | $12.2M | $15.93M | $15.67M | $15.44M | $12.83M | |
| $17.37M | — | — | — | $17.41M | $26.98M | $24.51M | $14.64M | $9.05M | |
| $36.36M | $35.22M | $58.82M | $47.31M | — | — | — | — | — | |
| $50.93M | $47.76M | $73.49M | $70.88M | $30.33M | $42.91M | $40.18M | $30.08M | $21.88M | |
| -$13.77M | -$12.19M | -$65.92M | -$65.76M | -$21.3M | -$30.91M | -$40.18M | -$30.08M | -$21.88M | |
| — | -34.25% | -871.25% | -1283.35% | -235.78% | -257.57% | — | — | — | |
| $5.7M | $7.74M | $9.41M | $3.96M | $2.17M | $4.3M | $3.03M | — | — | |
| $793K | $929K | $1.42M | $2.74M | $476K | $123K | $521K | $1.88M | $1.23M | |
| -$4.06M | -$5.7M | -$10.66M | -$1.24M | -$3.19M | -$4.17M | -$2.51M | $1.87M | $1.23M | |
| — | $0 | $0 | $0 | — | — | — | — | — | |
| -$17.83M | -$17.89M | -$76.58M | -$67M | -$24.49M | -$35.08M | -$42.69M | -$28.21M | -$20.65M | |
| — | -50.27% | -1012.15% | -1307.47% | -271.11% | -292.33% | — | — | — | |
| — | — | — | — | — | — | — | — | -$20.65M | |
| — | — | — | -$67M | -$24.46M | -$35.11M | -$42.71M | -$28.17M | -$20.67M | |
| USD/shares | — | -$1.68 | -$14.80 | -$14.80 | -$7.20 | — | — | — | — |
| USD/shares | — | -$1.68 | -$14.80 | -$14.80 | -$7.20 | — | — | — | — |
| shares | — | 10.65M | 5.18M | 4.53M | 3.42M | 2.7M | 2.5M | 2.49M | 1.47M |
| shares | — | 10.65M | 5.18M | 4.53M | 3.42M | 2.7M | 2.5M | 2.49M | 1.47M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Segment | $35,577,000 | $7,566,000 | $5,124,000 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|
| License and Collaboration Revenue Milestones | $38,000,000 | $38,000,000 | $38,000,000 | — | — | — |
| Product | — | $15,285,000 | — | $6,574,000 | $4,658,000 | $0 |
| Collaboration | — | — | — | $992,000 | $466,000 | $9,032,000 |
| License And Collaboration Revenue Commercial Supply And Development | — | $2,300,000 | — | $1,000,000 | — | — |
| License and Collaboration Revenue | — | $20,292,000 | — | $992,000 | — | — |